Ben Jemaa et al. Journal of Experimental & Clinical Cancer Research 2010, 29:171 http://www.jeccr.com/content/29/1/171 Page 6 of 9 Figure 3 Association between immunostaining intensity of CD34, PSMA and PSA expression among tissue CD34 levels in benign prostatic hyperplasia (BPH) (A) and prostate cancer (PC) patients (B). Values were expressed as mean ± SEM. Average optical densities were evaluated only in patients showing immunopositivity. Statistical analysis refers to each antibody separately. Values denoted by different superscripts are significantly different from each other. Those values sharing the same superscript are not statistically different from each other. Statistical analysis refers to each antibody separately. Significance was determined at p≤0. 05; 2.34: Mean O.D of CD34 value in NP; 8: Mean O.D of CD34 value in BPH and 12.08: Mean O.D of CD34 value in PC patients. carcinomatous prostate samples. This is seems to be related to two mechanisms of growth of this prostate cancer tissue (data not shown). The study of distinct pattern of prostate tumor profiles produced by prostate epithelial cells depending on positive immunoreactions to PSA and PSMA showed a high immunoexpression of the profile (PSA+, PSMA+) in all histological prostate tissues. In this latter profile, PSA and PSMA are more expressed in BPH compared to NP. The PSMA was highest in neoplastic cells, whereas PSA was highest in benign cells in the same profile. For the profile (PSA+, PSMA-) expression levels decreases between normal prostate, benign prostatic tissue and primary prostate cancer. Inversely, the profile (PSA-, PSMA+) expression increases from NP, BPH to PC patients. Compared to BPH patients, the profile (PSA-, PSMA-) is absent in